217 related articles for article (PubMed ID: 32594749)
1. Biomarkers of neoadjuvant/adjuvant endocrine therapy for ER-positive/HER2-negative breast cancer.
Ueno T
Chin Clin Oncol; 2020 Jun; 9(3):35. PubMed ID: 32594749
[TBL] [Abstract][Full Text] [Related]
2. Prognostic and Predictive Biomarkers of Endocrine Responsiveness for Estrogen Receptor Positive Breast Cancer.
Ma CX; Bose R; Ellis MJ
Adv Exp Med Biol; 2016; 882():125-54. PubMed ID: 26987533
[TBL] [Abstract][Full Text] [Related]
3. Impact of combining the progesterone receptor and preoperative endocrine prognostic index (PEPI) as a prognostic factor after neoadjuvant endocrine therapy using aromatase inhibitors in postmenopausal ER positive and HER2 negative breast cancer.
Kurozumi S; Matsumoto H; Inoue K; Tozuka K; Hayashi Y; Kurosumi M; Oyama T; Fujii T; Horiguchi J; Kuwano H
PLoS One; 2018; 13(8):e0201846. PubMed ID: 30080878
[TBL] [Abstract][Full Text] [Related]
4. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
[TBL] [Abstract][Full Text] [Related]
5. Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution?
Freedman OC; Verma S; Clemons MJ
Cancer Treat Rev; 2005 Feb; 31(1):1-17. PubMed ID: 15707700
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant endocrine therapy in locally advanced estrogen or progesterone receptor-positive breast cancer: determining the optimal endocrine agent and treatment duration in postmenopausal women-a literature review and proposed guidelines.
Madigan LI; Dinh P; Graham JD
Breast Cancer Res; 2020 Jul; 22(1):77. PubMed ID: 32690069
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant endocrine therapy for estrogen receptor-positive primary breast cancer.
Yamamoto Y; Goto-Yamaguchi L; Takeno M; Yamamoto-Ibusuki M
Chin Clin Oncol; 2020 Jun; 9(3):30. PubMed ID: 32279525
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant endocrine therapy: Patient selection, treatment duration and surrogate endpoints.
Yeo B; Dowsett M
Breast; 2015 Nov; 24 Suppl 2():S78-83. PubMed ID: 26255746
[TBL] [Abstract][Full Text] [Related]
9. Optimizing the use of neoadjuvant endocrine therapy.
Agrawal LS; Mayer IA
Curr Oncol Rep; 2015 Jul; 17(7):33. PubMed ID: 26008918
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Meta-analysis.
Spring LM; Gupta A; Reynolds KL; Gadd MA; Ellisen LW; Isakoff SJ; Moy B; Bardia A
JAMA Oncol; 2016 Nov; 2(11):1477-1486. PubMed ID: 27367583
[TBL] [Abstract][Full Text] [Related]
11. Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study.
Iwata H; Masuda N; Yamamoto Y; Fujisawa T; Toyama T; Kashiwaba M; Ohtani S; Taira N; Sakai T; Hasegawa Y; Nakamura R; Akabane H; Shibahara Y; Sasano H; Yamaguchi T; Sakamaki K; Bailey H; Cherbavaz DB; Jakubowski DM; Sugiyama N; Chao C; Ohashi Y
Breast Cancer Res Treat; 2019 Jan; 173(1):123-133. PubMed ID: 30242578
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant Endocrine Therapy: Who Benefits Most?
Grossman J; Ma C; Aft R
Surg Oncol Clin N Am; 2018 Jan; 27(1):121-140. PubMed ID: 29132556
[TBL] [Abstract][Full Text] [Related]
13. Molecular essence and endocrine responsiveness of estrogen receptor-negative, progesterone receptor-positive, and HER2-negative breast cancer.
Yu KD; Jiang YZ; Hao S; Shao ZM
BMC Med; 2015 Oct; 13():254. PubMed ID: 26437901
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant endocrine treatment for estrogen receptor (ER)-positive/HER2-negative breast cancer.
Kubo M
Chin Clin Oncol; 2020 Jun; 9(3):33. PubMed ID: 32527118
[TBL] [Abstract][Full Text] [Related]
15. Clinical Utility of Neoadjuvant Endocrine Therapy for Hormone Receptor Positive Breast Cancer.
Kolberg HC; Aktas B; Liedtke C
Rev Recent Clin Trials; 2017; 12(2):67-72. PubMed ID: 28155606
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant therapy for ER-positive breast cancers.
Colleoni M; Montagna E
Ann Oncol; 2012 Sep; 23 Suppl 10():x243-8. PubMed ID: 22987970
[TBL] [Abstract][Full Text] [Related]
17. Role of adjuvant endocrine therapy in early-stage breast cancer.
Muss HB
Semin Oncol; 2001 Aug; 28(4):313-21. PubMed ID: 11498825
[TBL] [Abstract][Full Text] [Related]
18. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant Endocrine Therapy in Breast Cancer Upregulates the Cytotoxic Drug Pump ABCG2/BCRP, and May Lead to Resistance to Subsequent Chemotherapy.
Baxter DE; Kim B; Hanby AM; Verghese ET; Sims AH; Hughes TA
Clin Breast Cancer; 2018 Dec; 18(6):481-488. PubMed ID: 30055962
[TBL] [Abstract][Full Text] [Related]
20. Endocrine therapy as adjuvant or neoadjuvant therapy for breast cancer: selecting the best agents, the timing and duration of treatment.
Li JJ; Shao ZM
Chin Clin Oncol; 2016 Jun; 5(3):40. PubMed ID: 27164856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]